Saad, Ayman http://orcid.org/0000-0003-0003-0130
Taneja, Alankrita
Di Stasi, Antonio
Sarmad, Rehan
Kukkamalla, Rivvi
Costa, Luciano http://orcid.org/0000-0001-5362-2469
Salzman, Donna
Innis-Shelton, Racquel
Chewning, Joseph H.
Meredith, Ruby F.
Hauptfeld, Vera
Langford, Samantha
Plessala, KirbyAnn
Bhatia, Ravi
Lamb, Lawrence S
Mineishi, Shin
Article History
Received: 5 March 2018
Revised: 18 March 2018
Accepted: 24 March 2018
First Online: 4 May 2018
Conflict of Interest
: Ayman Saad: royalty for licensing of intellectual property (Incysus Biomedical), grant support (American Porphyria foundation), consultant fees (Actinium Pharma Inc), Research support (Astellas and Fate Therapeutics), and Honoraria (Alexion and Spectrum Pharmaceutical). Lawrence lamb: Chair, Incysus Scientific Advisory Board. The authors declare that they have no conflict of interest.